Cargando…
Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis
Colorectal cancer (CRC) is the second-most common malignant disease worldwide, and metastasis is the main culprit of CRC-related death. Metachronous metastases remain to be an unpredictable, unpreventable, and fatal complication, and tracing the molecular chain of events that lead to metastasis woul...
Autores principales: | Kortüm, Benedikt, Radhakrishnan, Harikrishnan, Zincke, Fabian, Sachse, Christoph, Burock, Susen, Keilholz, Ulrich, Dahlmann, Mathias, Walther, Wolfgang, Dittmar, Gunnar, Kobelt, Dennis, Stein, Ulrike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9507965/ https://www.ncbi.nlm.nih.gov/pubmed/36008464 http://dx.doi.org/10.1038/s41388-022-02407-6 |
Ejemplares similares
-
The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis
por: Kobelt, Dennis, et al.
Publicado: (2021) -
Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker
por: Schmid, Felicitas, et al.
Publicado: (2022) -
Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy
por: Dahlmann, Mathias, et al.
Publicado: (2020) -
Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial
por: Burock, Susen, et al.
Publicado: (2018) -
Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1
por: Juneja, Manisha, et al.
Publicado: (2017)